vs
Ginkgo Bioworks Holdings, Inc.（DNA）与PLUMAS BANCORP（PLBC）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是PLUMAS BANCORP的1.2倍（$33.4M vs $28.6M），PLUMAS BANCORP同比增速更快（35.1% vs -23.8%），PLUMAS BANCORP自由现金流更多（$20.3M vs $-47.7M），过去两年PLUMAS BANCORP的营收复合增速更高（20.8% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
Plumas Bancorp是一家美国银行控股公司，通过旗下子公司Plumas Bank开展业务，为加利福尼亚州北部及内华达州的个人客户、中小企业和本地社区机构提供存款、各类贷款、财富管理等综合零售及商业银行服务。
DNA vs PLBC — 直观对比
营收规模更大
DNA
是对方的1.2倍
$28.6M
营收增速更快
PLBC
高出58.9%
-23.8%
自由现金流更多
PLBC
多$68.0M
$-47.7M
两年增速更快
PLBC
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $28.6M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 48.9% |
| 净利率 | — | — |
| 营收同比 | -23.8% | 35.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.41 | $1.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAPLBC
| Q4 25 | $33.4M | $28.6M | ||
| Q3 25 | $38.8M | $27.4M | ||
| Q2 25 | $49.6M | $20.5M | ||
| Q1 25 | $48.3M | $21.8M | ||
| Q4 24 | $43.8M | $21.2M | ||
| Q3 24 | $89.0M | $21.1M | ||
| Q2 24 | $56.2M | $20.6M | ||
| Q1 24 | $37.9M | $19.6M |
净利润DNAPLBC
| Q4 25 | — | — | ||
| Q3 25 | $-80.8M | $5.1M | ||
| Q2 25 | $-60.3M | $6.3M | ||
| Q1 25 | $-91.0M | $7.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.4M | $7.8M | ||
| Q2 24 | $-217.2M | $6.8M | ||
| Q1 24 | $-165.9M | $6.3M |
营业利润率DNAPLBC
| Q4 25 | -211.9% | 48.9% | ||
| Q3 25 | -231.8% | 25.2% | ||
| Q2 25 | -132.1% | 42.2% | ||
| Q1 25 | -184.1% | 46.1% | ||
| Q4 24 | -236.3% | 50.3% | ||
| Q3 24 | -62.0% | 50.6% | ||
| Q2 24 | -396.7% | 45.1% | ||
| Q1 24 | -469.1% | 42.8% |
净利率DNAPLBC
| Q4 25 | — | — | ||
| Q3 25 | -207.9% | 18.8% | ||
| Q2 25 | -121.6% | 30.8% | ||
| Q1 25 | -188.2% | 33.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -63.3% | 37.1% | ||
| Q2 24 | -386.4% | 32.9% | ||
| Q1 24 | -437.3% | 31.9% |
每股收益（稀释后）DNAPLBC
| Q4 25 | $-1.41 | $1.56 | ||
| Q3 25 | $-1.45 | $0.73 | ||
| Q2 25 | $-1.10 | $1.05 | ||
| Q1 25 | $-1.68 | $1.20 | ||
| Q4 24 | $-1.91 | $1.30 | ||
| Q3 24 | $-1.08 | $1.31 | ||
| Q2 24 | $-4.23 | $1.14 | ||
| Q1 24 | $-3.32 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $80.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $261.1M |
| 总资产 | $1.1B | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAPLBC
| Q4 25 | $422.6M | $80.6M | ||
| Q3 25 | $495.5M | $87.3M | ||
| Q2 25 | $559.4M | $79.3M | ||
| Q1 25 | $325.3M | $87.3M | ||
| Q4 24 | $561.6M | $82.0M | ||
| Q3 24 | $616.2M | $118.0M | ||
| Q2 24 | $730.4M | $109.9M | ||
| Q1 24 | $840.4M | $128.2M |
股东权益DNAPLBC
| Q4 25 | $508.6M | $261.1M | ||
| Q3 25 | $559.8M | $245.9M | ||
| Q2 25 | $613.0M | $193.1M | ||
| Q1 25 | $647.4M | $187.6M | ||
| Q4 24 | $716.1M | $177.9M | ||
| Q3 24 | $797.9M | $181.9M | ||
| Q2 24 | $833.1M | $165.2M | ||
| Q1 24 | $987.3M | $161.5M |
总资产DNAPLBC
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.2B | $2.2B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.6B | $1.6B | ||
| Q1 24 | $1.6B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $21.6M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $20.3M |
| 自由现金流率自由现金流/营收 | -142.8% | 70.9% |
| 资本支出强度资本支出/营收 | 0.0% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $34.4M |
8季度趋势，按日历期对齐
经营现金流DNAPLBC
| Q4 25 | $-47.7M | $21.6M | ||
| Q3 25 | $-31.6M | $5.6M | ||
| Q2 25 | $-40.3M | $2.1M | ||
| Q1 25 | $-51.5M | $7.5M | ||
| Q4 24 | $-42.4M | $30.5M | ||
| Q3 24 | $-103.5M | $8.0M | ||
| Q2 24 | $-84.4M | $5.1M | ||
| Q1 24 | $-89.3M | $9.2M |
自由现金流DNAPLBC
| Q4 25 | $-47.7M | $20.3M | ||
| Q3 25 | — | $4.8M | ||
| Q2 25 | $-40.3M | $2.0M | ||
| Q1 25 | $-59.1M | $7.3M | ||
| Q4 24 | $-56.1M | $29.8M | ||
| Q3 24 | $-118.6M | $7.8M | ||
| Q2 24 | $-111.4M | $4.8M | ||
| Q1 24 | $-96.0M | $9.0M |
自由现金流率DNAPLBC
| Q4 25 | -142.8% | 70.9% | ||
| Q3 25 | — | 17.5% | ||
| Q2 25 | -81.2% | 9.9% | ||
| Q1 25 | -122.4% | 33.7% | ||
| Q4 24 | -128.0% | 141.0% | ||
| Q3 24 | -133.2% | 37.1% | ||
| Q2 24 | -198.2% | 23.5% | ||
| Q1 24 | -252.9% | 45.8% |
资本支出强度DNAPLBC
| Q4 25 | 0.0% | 4.6% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 15.8% | 0.8% | ||
| Q4 24 | 31.3% | 3.2% | ||
| Q3 24 | 16.9% | 0.7% | ||
| Q2 24 | 48.1% | 1.1% | ||
| Q1 24 | 17.7% | 1.0% |
现金转化率DNAPLBC
| Q4 25 | — | — | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.33× | ||
| Q1 25 | — | 1.04× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.02× | ||
| Q2 24 | — | 0.75× | ||
| Q1 24 | — | 1.46× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
PLBC
暂无分部数据
